People · Operator
Named in public records as an officer, director or promoter · active 2017–2024 · Biotechnology, Healthtech
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Unicycive Therapeutics, Inc. | — | Biotechnology | Series C | $81.7M | $500.3M | 2023 |
| Guardion Health Sciences, Inc. | — | Healthtech | Series A | $8.4M | $7.9M | 2017 |
John Townsend at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside John Townsend on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| John Ryan | 1 | 17 |
| Sandeep Laumas | 1 | 6 |
| David Evans | 1 | 6 |
| Robert Weingarten | 1 | 3 |
| Gaurav Aggarwal | 1 | 3 |
| Vincent J. Roth | 1 | 2 |
| Shalabh Gupta | 1 | 2 |
| Mark Goldstone | 1 | 2 |
| Gordon Bethwaite | 1 | 2 |
| Sara Kenkare-Mitra | 1 | 1 |
| Michael Favish | 1 | 1 |
| Vincent Roth | 1 | 1 |
| Brigitte Schiller | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.